Published in final edited form as:

Alzheimers Dement. 2014 July ; 10(4): 477–484.e1. doi:10.1016/j.jalz.2013.06.003.

A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank

Jon B. Toledo^a, Vivianna M. Van Deerlin^a, Edward B. Lee^a, EunRan Suh^a, Young Baek^a, John L. Robinson^a, Sharon X. Xie^b, Jennifer McBride^a, Elisabeth M. Wood^a, Theresa Schuck^a, David J. Irwin^a, Rachel G. Gross^c, Howard Hurtig^c, Leo McCluskey^c, Lauren Elman^c, Jason Karlawish^c, Gerard Schellenberg^a, Alice Chen-Plotkin^c, David Wolk^c, Murray Grossman^c, Steven E. Arnold^{c,d}, Leslie M. Shaw^a, Virginia M.-Y. Lee^a, and John Q. Trojanowski^{a,*}

^aDepartment of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, Philadelphia, Pennsylvania, USA

^bDepartment of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

^cDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

^dDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Abstract

Neurodegenerative diseases (NDs) are defined by the accumulation of abnormal protein deposits in the central nervous system (CNS), and only neuropathological examination enables a definitive diagnosis. Brain banks and their associated scientific programs have shaped the actual knowledge of NDs, identifying and characterizing the CNS deposits that define new diseases, formulating staging schemes, and establishing correlations between neuropathological changes and clinical features. However, brain banks have evolved to accommodate the banking of biofluids as well as DNA and RNA samples. Moreover, the value of biobanks is greatly enhanced if they link all the multidimensional clinical and laboratory information of each case, which is accomplished, optimally, using systematic and standardized operating procedures, and in the framework of multidisciplinary teams with the support of a flexible and user-friendly database system that facilitates the sharing of information of all the teams in the network. We describe a biobanking system that is a platform for discovery research at the Center for Neurodegenerative Disease Research at the University of Pennsylvania.

Keywords

Cerebrospinal fluid; Plasma; Serum; Autopsy; Neurodegeneration; Alzheimer's Disease; Dementia; Genetics; Parkinson's Disease; Frontotemporal lobar degeneration

1. Introduction

The term *neurodegenerative disease* (ND) encompasses a heterogeneous group of diseases defined by the progressive and relentless degeneration of selectively vulnerable populations of neurons and glia that are almost always associated with the deposition of abnormal proteins, usually as amyloid, in the central nervous system (CNS) that mainly manifest clinically as cognitive, movement, language, and behavioral disorders, and/or motor neuron disease. The most common diseases are classified in the following groups: Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) resulting from tau immunoreactive deposits or FTLD resulting from transactive response (TAR) DNA binding protein 43 immunoreactive deposits (FTLD-TDP-43), amyotrophic lateral sclerosis (ALS), synucleinopathies resulting from the deposition of pathological α -synuclein, and prion diseases. The neuropathological hallmarks of these diseases are identified as a result of the study of brain and DNA samples, and biobanks enable the collection of tissue and biofluid samples to accelerate the discovery of pathological subtypes and DNA to make associations between certain pathological subtypes with specific genetic abnormalities [1–6]. The discovery of the proteins and genes linked to the formation of the CNS deposits shaped the classification of NDs by establishing the diagnostic criteria for different NDs [7–13]. Although NDs such as AD, FTLD, and Parkinson's disease (PD) have characteristic clinical phenotypes that define them, there is some phenotypic heterogeneity. Therefore, clinicopathological correlation varies based on the phenotype [14] and neuropathological assessment is still the gold standard for definitive diagnosis of NDs. In addition, it is common to find coincident ND diagnoses at the pathological level [14]. Cerebrospinal fluid (CSF) levels of amyloid- β and total and phosphorylated tau correlate with deposition of abnormal proteins in the brain in AD [15] and can predict accurately an underlying AD pathology [14]. However, there are currently no reproducible and accurate molecular diagnostic biomarkers for synucleinopathies [e1] and FTLD [e2] whereas plasma amyloid- β levels have not proved useful for diagnostic classification of AD [16]. Moreover, positron emission tomography and single photon emission computed tomography can detect the dopaminergic deficit even at premotor stages of PD [17], and amyloid positron emission tomographic imaging correlates with fibrillar amyloid brain deposits [18,e3]. These advances notwithstanding, it remains a great challenge to predict the ultimate pathological diagnosis while patients are living. Nevertheless, achieving an accurate diagnosis in life is particularly important because there are many clinical drug trials designed to target a specific molecular mechanism or pathological protein that, if successful, will enable targeted therapy for NDs to delay the onset or the halt progression of disease. Because biofluids are easily accessible from living patients, a great deal of effort is focused on finding ways to extract diagnostic information from them. The emergence of new technologies that are able to screen for several proteins [19,e4] in biofluids, such as CSF and plasma, has led to further interest in these samples and to the establishment of biofluid banks that allow the testing of these new technologies in well-characterized recruited cohorts. However, to maximize the utility of biofluid samples for the evaluation of new biomarkers, the subjects from which they were obtained must have a reliable and accurate clinical and neuropathological diagnosis.

Last, genetic discoveries for NDs have accelerated efforts to delineate molecular mechanisms of NDs. Pathogenic gene mutations and genetic risk variants have been identified for NDs in both small and large collaborative studies. Tissue and DNA samples stored in biobanks [20–22,e5] have enabled these discoveries. Because genetic risk factors for neurodegenerative diseases are better studied and combined with biomarker data, this will lead to new models for diagnosis and prognosis.

Although the number of autopsies worldwide is declining [23,24], families and patients support autopsy-based research altruistically [25–27], and autopsies have a recognized educational and teaching purpose [28]. In addition, still in this century a significant number of autopsies detect clinically important missed diagnoses, although the rate of autopsy-detected diagnostic errors has declined (including nonneurological cause of death) [29]. This is even more important in the case of NDs that show, overall, a clinicopathological correlation of 81% in specialized centers [14]. One of the most important factors for the success of autopsy programs is the clinician's attitude toward autopsies [28]. Therefore, the creation of AD centers and Udall Parkinson's Disease Centers in the United States, and other initiatives in Europe [e6] and Australia [e7], is enabling researchers to access standardized, high-quality samples from patients with NDs in collaboration with clinicians. Recently, our group proposed a model for comprehensive AD centers that would not be limited only to the study of AD but would also include the study of PD, FTLN, ALS, and vascular dementia [30], because of their frequent overlap [14,31], using a multidisciplinary, patient-oriented clinical and basic research strategy. To be able to take advantage of all the new technologies and to build onto the archive of biosamples and information, the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania (UPenn) established the Neuropathology, Biomarker, and Genetics Biobank (NBGB) as well as the Integrated Neurodegenerative Disease Database (INDD) to monitor biosamples and data collection. In this article, we describe the integrative approach of this biobank together with the different clinical centers [30] that gather clinical data, and genetic and biofluid samples and brains of well-characterized, longitudinally monitored patients with different NDs at UPenn (Fig. 1). In addition, we describe the different basic research, translational, and clinical studies that are developed in this framework.

2. Integrated Neurodegenerative Disease Database

The INDD integrates the information from the NBGB and all the clinical centers involved in the study of NDs at UPenn [32]. Although the different clinical centers have used their own identifiers (IDs) historically, each subject in the database has been assigned a unique universal anonymized ID (IN-DDID). Briefly, the INDD is a relational database implemented with Microsoft SQL Server (version 2008; Microsoft Corporation, Redmond, WA, USA). To offer easy access to members of the different UPenn research groups or cores, a Web-driven online database was created using Microsoft ASP.NET MVC 3 technology along with HTML (HyperText Markup Language) and JavaScript for the user interface. Further details on the INDD structure are described in detail in Xie and colleagues [32]; centers interested in implementing a similar system can contact the corresponding author for further information.

The directors of each of the biosample core areas form a biosample request review committee that evaluates and grants access to the INDD on request from UPenn researchers and research assistants working with them. The access permission also specifies the level of access granted. Users have to undergo Health Insurance Portability and Accountability Act training and be included in the corresponding institutional review board-approved protocols to gain access to the database. After they meet the necessary requirements, researchers are authenticated, and different levels of data access to the tables of the databases are granted to them. The INDD has several security measures, and two systems for regular, periodic backup are also implemented [32]. To ensure the entry of the data is accurate, there is double entry of randomly selected data, and 10% of the original source records are checked quarterly. There are also consistency checks and hard and soft stops, which have been described previously [32]. There are five data tables (autopsy, microscopic study, inventory, genetics, and biofluids) that are used for input, visualization, and extraction of data from the NBGB, as described in the corresponding sections that follow.

An example of how the database is updated constantly and of how new features are added is the recent inclusion of two search engines to the INDD. The first one is based on Structured Query Language and enables users to save their own specific queries, modify them, and update them every time if needed. In addition, a new querying system based on the same online Web user interface called INQuery has been implemented for researchers to assist them with their database queries, including selecting different fields from tables and merging data automatically. Subjects can be selected based on a clinical core or NBGB basis, or on a predefined list of IDs. All the generated data are exported into Excel format for further research use.

3. Recruitment of patients and sample collection across clinical cores

Because of the labor, cost, and logistic implications associated with autopsy procedures, the NBGB selects subjects who are followed in the clinical centers, have detailed clinical information, and, in most cases, additional biofluid, neuroimaging, and genetic data/samples to be included in the brain donation program. The Alzheimer's Disease Core Center (ADCC), the Penn Memory Center, the Frontotemporal Degeneration Center, the ALS Center, the Parkinson's Disease and Movement Disorder Clinic, and the Penn Udall Center for Parkinson's Research each have protocols approved by the institutional review board to recruit patients, along with their clinical data, into research studies. In addition, these centers invite patients to participate in the brain donation program. Although the table fields that contain the clinical and demographic information from the different clinical centers differ, the recent integration of the National Alzheimer's Coordinating Center FTLD module for use in the National Institute on Aging-funded AD centers will help increase the overlap between the data gathered by this core and the AD centers. Consensus meetings have been held to establish a set of common diagnoses categories to be used. Plasma and CSF samples are collected in the individual clinical cores as described previously [33,34]. In addition, the ADCC and the Penn Memory Center have collected serum samples.

4. Processing, tracking, and storing samples by the biofluids section

Biofluid samples are collected up to 3:00 PM during working hours to ensure that samples are processed after they are obtained the same day. Processing of plasma and CSF in the NBGB follows the same standard operating procedures (SOPs) as the Alzheimer's Disease Neuroimaging Initiative (ADNI) [35]. For CSF sampling, 4 hours of fasting is required, although it is not required for blood samples. CSF is collected using clear polypropylene tubes and aliquoted into 0.5-mL samples in 1.5-mL cryogenic tubes after collection without a centrifugation step. Plasma and serum samples are obtained using Lavender top K2 ethylenediaminetetraacetic acid (EDTA) tubes (BD Vacutainer, Franklin Lanes, NJ, USA) and serum separation (SST) tubes (BD Vacutainer, Franklin Lanes, NJ, USA), respectively. Samples are centrifuged at 3000g (equal to 1962 rcf) for 15 minutes at 4°C, and plasma samples are aliquoted into 2.0-mL polypropylene cryovials (Corning cryovials, Acton, MA, USA) fitted with a silicone washer to ensure an air-tight seal. CSF is aliquoted immediately without undergoing centrifugation. Samples from the frontotemporal degeneration and ALS centers are sent to the CNDR for processing after sampling, whereas the ADCC, the Parkinson's Disease and Movement Disorder Clinic, and the Penn Udall Center for Parkinson's Research all process their own samples and send them already aliquoted and in sealed containers with dry ice. For further details on the SOPs for CSF and other biofluid collection and storage, please see the Alzheimer's Disease Neuroimaging Initiative SOPs which are the same as those used in the CNDR.

Tubes are labeled with center, processing date, INDDID, tube number (unique for each vial banked), and sample type (CSF, plasma, or serum). The INDD contains the number and type of available aliquots from each sample (CSF, plasma, or serum), day of sampling, the INDDID, sample ID, and the physical location of the samples. The aliquots are stored at –80°C in freezers dedicated specifically for banking human biofluid samples. These freezers have alarm settings to monitor temperature (high alarm at –70°C, low alarm at –90°C). Freezers are connected to a Sensaphone to alert caretakers if the freezers' temperature is compromised so samples can be moved to another location.

5. Nucleic acid banking and genotyping

Peripheral blood or saliva is collected from all consenting living individuals for extraction of DNA. Blood in PAXgene RNA preservative tubes (BD, Sparks, MD, USA) is collected from selected individuals from families with known genetic mutations for extraction of total RNA. Blood and saliva samples for DNA are transported to the genetics laboratory and are stored at 4°C until extraction; RNA tubes are frozen at –80°C until needed. In addition, DNA is extracted from all frozen brain tissues collected in the NBGC. DNA and RNA extractions are performed with commercial reagents using manual or semiautomated procedures. Extracted nucleic acid samples are stored at –30°C (DNA) or –80°C (RNA). Sample receipt and testing are tracked using the workflow module of a custom-designed Progeny Laboratory Information Management System relational database (version 8.2.06; Progeny Software, LLC, South Bend, IN). Sample information—such as source, quality, quantity, and storage location—is uploaded into the Progeny database and linked to the individual in the database. Each individual in Progeny is linked to a global database

individual by the IN-DDID. In the majority of cases, a third-generation pedigree is obtained by a genetic counselor to document any family history of NDs and ethnicity. Individuals in the Progeny database can be added to a pedigree so that the relationship between different individuals in a family and their clinical status can be visualized easily. Interested and available family members of primarily familial cases are offered participation in the research studies.

Using the provided Progeny open database connectivity drivers, an external interface to Progeny's internal database was implemented. This in-house-built interface provides the ability to import the matching clinical data fields from the INDD to the Progeny database and vice versa for genetic information. The importing feature is activated when a user creates a new patient record in Progeny. When a matching patient is found in the clinical databases, all the matching data fields are imported from the clinical database to the Progeny database. This automated transfer of data eliminates errors associated with manual entry. Furthermore, the INDD also transmits data to the Progeny database on a nightly scheduled data push. This feature allows two databases to have the identical data and be in synchrony. This feature prevents mismatched data in two different databases and provides the genetics group access to the most up-to-date clinical and neuropathological diagnoses, because these may change over time with new ND research advances.

The genetics core performs a variety of standard and unique genetic tests to evaluate for pathogenic mutations and genotype risk alleles. Because the genetics core is in a unique setting serving patients with AD, PD, FTLN, and ALS, a Pan-Neurodegenerative Disease-Oriented Risk Allele (PANDORA) panel was designed to provide a method for comprehensive genotyping of relevant common mutations and single nucleotide polymorphism (SNP) risk alleles in a time- and cost-effective manner for all four disease groups. PANDORA, performed on a Sequenom MassAR-RAY instrument, includes 52 single nucleotide genetic variants selected to represent the top hits from published genomewide association studies (GWAS) and the interests of the researchers in the different cores. A targeted next-generation sequencing panel has been designed to screen for known gene mutations/variants and to discover novel mutations in targeted genes.

Genetic testing and genotyping results—for example, apolipoprotein E genotype, microtubule-associated protein tau (MAPT) haplotype, and/or gene mutation status—are entered into custom-designed Progeny fields. The decision of which DNA sequencing or genotyping to perform on each sample is based on prior arrangements (apolipoprotein E for all ADCC cases), case-specific features (familial case), and/or special projects [e8–e10], which are reviewed at a biweekly genetics case conference. Relevant genetic information (sequencing and genotyping) are synchronized nightly to the INDD from Progeny. Only selected individuals from each clinical group have access to the genetic information to limit access to genetic information only to those individuals with a need to know. A genetics table with summary fields of gene sequencing results and SNP genotypes is available in the INQuery system to perform searches in combination with clinical, biomarker, and neuropathological features. In addition, subjects who have been included in previous GWAS studies [21,e11,e12] are identified in the INDD, and a graphic–user interface is being developed to extract specific SNPs for all the subjects. Any presymptomatic (prodromal) at-

risk individuals from families with a known autosomal dominant mutation who wish to learn their genetic status are advised on their intent to access this information. However, this information is then regenerated by clinical testing performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified molecular pathology laboratory at the Hospital of the University of Pennsylvania (HUP).

6. Brain and spinal cord processing and storage

As described earlier, patients with NDs are recruited into the autopsy program by the different clinical cores. An informed consent is signed by the patient and/or legal guardian of the patient [36]. When the deceased patient is in the Philadelphia area, the brain and spinal cord extraction is undertaken at the HUP morgue. Information is provided to the families with instructions that the funeral director or nursing home should contact HUP pathology staff to arrange transportation to the hospital as soon as feasible. Several phone numbers are provided so families are able to reach laboratory staff 24 hours a day, 365 days a year. At time of death, a HUP medical doctor contacts the family to obtain final consent of tissue donation for research purposes. The funeral director then works with the family to arrange transport to and from the hospital.

When the patient resides in the region of the HUP, HUP pathology assistants are available for brain removal at local hospitals or funeral homes for transport of the brain back to the HUP autopsy suite. Patients who lived outside the region are considered remote autopsies. A national company (Regional Pathology and Autopsy Services, Oakland, CA) is contacted to hire a local pathologist. In these cases, a brain removal and shipping protocol is provided to the private pathologist, who separates the cerebral hemispheres. The left hemisphere and brain stem are immersed in 10% neutral buffered formalin for 2 weeks whereas the right hemisphere is sliced coronally and frozen before shipment to the CNDR. Although previously the whole spinal cord was obtained for ALS cases only, in the new informed consent all patients are asked to donate the brain and spinal cord independent of clinical diagnosis.

The autopsy-related information is contained in two tables in the INDD. The first one contains the demographic, macroscopic, and diagnostic data (Table EA1). Most of the fields included in this table are drop-down menus to avoid typing errors or the use of nonstandardized categories. The final clinical diagnosis is established and confirmed at the time of death by the clinician who monitored the patient. To use standardized diagnostic categories across the different clinical cores, a consensus meeting of all the directors of the clinical cores is periodically held to revise a common set of diagnostic categories across centers. The second autopsy data table in the INDD contains the semiquantitative scores for all the areas included in the routine research diagnostic workup (Table EA2), with fields for additional neocortical, subcortical, brainstem, and spinal cord areas.

The sampling procedure is performed by a prosector and an assistant. The prosector is responsible for the brain dissection and writing the gross report under the guidance of a board-certified neuropathologist. The assistant prepares and presents the specimen containers during the dissection and records the prosector's observations for later entry to

the database. After demographic information, brain weight and postmortem interval (defined as the time between death of the patient and the autopsy procedure) are obtained, and the brain is examined for any macroscopic lesions. The circle of Willis and the basilar artery are examined, and the extent as well as the severity of atherosclerotic changes are noted using a semiquantitative scale. The surface pH of the brain in the frontal and occipital cortex is measured and recorded at this time as a quality control measure of the samples [37,38]. The brainstem is separated from the hemispheres with a cut between the superior and inferior corpora quadrigemina and then the hemispheres are separated with a cut along the interhemispheric fissure. At this point, pictures of medial and lateral aspects of the hemispheres and the rostral view of the brainstem and cerebellum are taken. In addition, any abnormal macroscopic findings are also documented. Cortical and subcortical samples are taken from the left hemisphere for odd-numbered autopsy cases, whereas the right hemisphere is selected in cases with even autopsy numbers. In cases with an asymmetric involvement, sampling may be changed or may become bilateral. Sampled areas are detailed in Table EA2; all areas are fixed using 10% neutral buffered formalin for one set of blocks, and 70% ethanol with 150 mmol NaCl for another set of blocks. This dual-fixative approach takes into account the fact that some epitopes or proteins are sensitive differentially to cross-linking vs. other denaturing fixatives [39–41]. Before cutting, the following areas are marked with ink to facilitate sampling and tissue bagging at later stages: the primary motor cortex is marked in black, the primary sensory cortex is marked in green, and the angular gyrus is marked in blue. Then, the selected hemisphere is cut serially into consecutive 1- to 1.5-cm-wide sections, and cortical and subcortical sections are taken (Table EA2). The tissue left from the sampled hemisphere as well as the sections from the contralateral hemisphere (also sectioned in 1- to 1.5-cm-wide sections) are frozen at -80°C . The brainstem is cut every centimeter, and sections for the midbrain (including the substantia nigra), upper pons (including the locus coeruleus), lower pons, and medulla are obtained. The cerebellum is also sectioned serially. A sample containing the dentate nucleus is fixed, and a cerebellar folia block of approximately 36 mm^3 is harvested for DNA extraction in the genetics core. The remaining brainstem and cerebellar tissue are placed on foil-lined stainless steel trays and stored at -80°C overnight. Any focal lesions such as suspected strokes, tumors, or other pathologies are also photographed and sampled. The following day, sections are bagged individually in serially numbered, resealable zipper storage bags, and the areas included in each bag are noted and included in the INDD. When classified, the samples are stored long term in -80°C freezers, and the freezer, shelf, and rack locations are entered in the INDD. The availability of frozen and fixed sections for each case is recorded in the tissue tracking table (Table EA3). The same security measures described for the biofluid samples are implemented in the freezers used for tissue storage. Nevertheless, brains with different diseases are distributed evenly in the different freezers to avoid a thaw that could affect all the samples corresponding to a specific disease. Notably, such an event has not occurred in the more than 25 years of the CNDR brain bank. Also, the day after the autopsy, harvested tissue sections are cassetted and, after another fixing cycle, they are embedded in paraffin and cut into 6- to $10\text{-}\mu\text{m}$ sections for diagnosis. A more detailed description of tissue processing and storing has been described previously by CNDR investigators [39,40] and by other groups [42].

For the routine diagnostic procedure, the sections detailed in Table EA2 are stained with hematoxylineosin to quantify neuron loss and gliosis, and the following primary antibodies are used for the detection of abnormal proteins: nab228 (monoclonal antibody [mAb], 1:8000, generated in CNDR) [43] to detect amyloid deposits and for Thal staging [44], phosphorylated tau PHF-1 (mAb, 1:1000, a gift from Dr. Peter Davies) to detect phosphorylated tau deposits, pS409/410 (mAb, 1:500, a gift from Dr. Manuela Neumann) to detect phosphorylated TDP-43 deposits [3], and Syn303 (mAb, 1:16,000, generated in the CNDR) to detect the presence of pathological conformation of α -synuclein [45]. Primary antibody binding is visualized with the avidin–biotin complex detection method (VECTASTAIN ABC kit; Vector Laboratories, Burlingame, CA) with ImmPACT diaminobenzidine peroxidase substrate (Vector Laboratories) as the chromogen. In addition, thioflavin S is used to grade the presence of neuritic plaques and to determine the Consortium to Establish a Registry for Alzheimer's Disease score [46,47]. All changes are rated using a semiquantitative scale (0 point, no changes; 0.5 point, rare; 1 point, mild; 2 points, moderate; 3 points, severe) and these gradings are introduced in the INDD. Also, for every studied area there is a string field to note any additional comments. All cases are reviewed by a board-certified neuropathologist for quality assurance and accurate grading.

The NBGB holds a training seminar and discussion of the autopsy protocols and procedures every 6 months, and there is a laboratory manual that contains all the sectioning, rating procedures, and bibliographic references for neuropathological diagnosis, and it is updated regularly. Moreover, a small primer that contains all the key sections to guide dissection is used during the dissection.

7. Examples of studies using samples from the NBGB

The framework that has been established during the past two decades in the NBGB has enabled researchers to pursue a large number of diverse studies that address NDs from different approaches. Some of these studies have defined brain deposits that characterized new subgroups of FTLT defined by TDP-43 [3] or fused in sarcoma protein pathologies [2]. These findings have been followed by a clinical and neuropathological characterization. The spectrum of the TDP-43 proteinopathies has been studied further [e13] and FTLT-TDP-43 has been characterized further based on the pattern and morphology of the deposition of TDP-43, which correlates with genetic findings and clinical phenotype [7,48]. The genetics core led a GWAS study based on neuropathologically diagnosed FTLT-TDP-43 cases that identified *TMEM106B* as a risk factor for FTLT-TDP-43 [e12], and the pathway implicated in the disease has been characterized recently by Chen-Plotkin and colleagues [e14]. The recently described *C9orf72* expansion has also shown a characteristic pattern of ubiquilin deposition in patients with ALS and FTLT-TDP-43, as described by Brettschneider and colleagues [e9], and the clinical characteristics have also been reported [e15]. Another example of translational research is the discovery by Cohen and colleagues [49] of how tau acetylation impairs tau–microtubule interactions and promotes pathological tau aggregation, and the following study by Irwin and colleagues [41] that characterized the deposits in AD and cases of FTLT resulting from tau immunoreactive deposits.

Other studies have sought to characterize neuropathological changes that underlie specific clinical features of NDs, such as dementia in PD [e16] or executive dysfunction, disease progression, and clinical symptoms in ALS [e17,e18]. Biomarker studies have dealt with the differential diagnosis of different NDs using neuropathologically validated diagnoses [14,34], evaluated the importance of coincident neuropathological diagnoses and the bias introduced by the use of a clinical diagnosis in a sample of consecutive neuropathologically validated cases [14], compared different CSF analytical platforms and derived transformation formulas [e19,e20], and investigated the possibility of using magnetic resonance imaging as a surrogate for CSF biomarkers [e21]. The genetics core not only has provided genetic information on the studied patients [e9,e15], but also has collaborated in large, multicenter GWASs [21,e11] and discovered *TARDBP* mutations that linked this gene and its encoded protein TDP-43 to the neurodegenerative process in TDP-43 proteinopathies [e22], as well as the studies described earlier. In addition, biosamples are available to outside investigators (for complete details, see [e23]).

8. Conclusions

In summary, we have presented an integrative approach that exemplifies the multidisciplinary integration of basic, translational, and clinical research teams in a single, dynamic framework centered on the NBGB, which gathers the clinical, biomarker, and autopsy samples and information of well-characterized subjects and enables different teams to gather efficiently large and rich data sets for studies across different NDs.

Acknowledgments

This work was supported by the National Institutes of Health (AG39510, AG033101, AG17586, AG10124, AG17586, NS053488, NS44266, and AG15116), the Wyncote Foundation, and the Koller Family Foundation. V. M.-Y. Lee is the John H. Ware, 3rd, Professor of Alzheimer's Disease Research. J. Q. Trojanowski is the William Maul Measey-Truman G. Schnabel, Jr., Professor of Geriatric Medicine and Gerontology. J. B. Toledo is supported in part by a grant from the Fundación Alfonso Martín Escudero.

References

1. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. *Am J Pathol*. 1998; 152:879–84. [PubMed: 9546347]
2. Neumann M, Rademakers R, Roeber S, Baker M, Kretschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. *Brain*. 2009; 132:2922–31. [PubMed: 19674978]
3. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*. 2006; 314:130–3. [PubMed: 17023659]
4. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. *Brain Pathol*. 1999; 9:681–93. [PubMed: 10517507]
5. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. *Allgemeine Z Psychiatrie Psychisch-Gerichtliche Med*. 1907; 64:146–8.
6. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. *Science*. 1982; 216:136–44. [PubMed: 6801762]

7. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTL-D-TDP pathology. *Acta Neuropathol.* 2011; 122:111–3. [PubMed: 21644037]
8. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathol.* 2010; 119:1–4. [PubMed: 19924424]
9. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. *Alzheimers Dement.* 2012; 8:1–13. [PubMed: 22265587]
10. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. *Arch Neurol.* 1999; 56:33–9. [PubMed: 9923759]
11. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology.* 2005; 65:1863–72. [PubMed: 16237129]
12. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology.* 2008; 71:670–6. [PubMed: 18725592]
13. Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz WK. Molecular biology and pathology of prion strains in sporadic human prion diseases. *Acta Neuropathol.* 2011; 121:79–90. [PubMed: 21058033]
14. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. *Acta Neuropathol.* 2012; 124:23–35. [PubMed: 22526019]
15. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid β -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. *Arch Neurol.* 2009; 66:382–9. [PubMed: 19273758]
16. Toledo JB, Shaw LM, Trojanowski JQ. Plasma A β measurements: a desired but elusive Alzheimer’s disease biomarker. *Alzheimers Res Ther.* 2013;5–8. [PubMed: 23374760]
17. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. *Prog Neurobiol.* 2011; 95:614–28. [PubMed: 21896306]
18. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. *JAMA.* 2011; 305:275–83. [PubMed: 21245183]
19. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology.* 2012; 79:897–905. [PubMed: 22855860]
20. Van Deerlin VM. The genetics and neuropathology of neurodegenerative disorders: perspectives and implications for research and clinical practice. *Acta Neuropathol.* 2012; 124:297–303. [PubMed: 22875012]
21. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet.* 2011; 43:699–705. [PubMed: 21685912]
22. Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. *Arch Neurol.* 2010; 67:161–70. [PubMed: 20142524]
23. Davies D, Graves D, Landgren A, Lawrence C, Lipsett J, MacGregor D, et al. The decline of the hospital autopsy: a safety and quality issue for healthcare in Australia. *Med J Austr.* 2004; 180:281–5.
24. Nemetz PN, Tanglos E, Sands LP, Fisher WP Jr, Newman WP III, Burton EC. Attitudes toward the autopsy: an 8-state survey. *Med Gen Med.* 2006; 8:80.
25. Garrick T, Howell S, Terwee P, Redenbach J, Blake H, Harper C. Brain donation for research: who donates and why? *J Clin Neurosci.* 2006; 13:524–8. [PubMed: 16678423]
26. Stevens M. Factors influencing decisions about donation of the brain for research purposes. *Age Ageing.* 1998; 27:623–9. [PubMed: 12675101]

27. Glaw XM, Garrick TM, Terwee PJ, Patching JR, Blake H, Harper C. Brain donation: who and why? *Cell Tissue Bank*. 2009; 10:241–6. [PubMed: 19184533]
28. Burton JL, Underwood J. Clinical, educational, and epidemiological value of autopsy. *Lancet*. 2007; 369:1471–80. [PubMed: 17467518]
29. Shojania KG, Burton EC, McDonald KM, Goldman L. Changes in rates of autopsy-detected diagnostic errors over time: a systematic review. *JAMA*. 2003; 289:2849–56. [PubMed: 12783916]
30. Trojanowski JQ, Arnold SE, Karlawish JH, Brunden K, Cary M, Davatzikos C, et al. Design of comprehensive Alzheimer's disease centers to address unmet national needs. *Alzheimers Dement*. 2010; 6:150–5. [PubMed: 20298979]
31. Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. *Acta Neuropathol*. 2010; 119:421–33. [PubMed: 20204386]
32. Xie SX, Baek Y, Grossman M, Arnold SE, Karlawish J, Siderowf A, et al. Building an integrated neurodegenerative disease database at an academic health center. *Alzheimers Dement*. 2011; 7:e84–93. [PubMed: 21784346]
33. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. *Ann Neurol*. 2011; 69:655–63. [PubMed: 21520231]
34. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. *Ann Neurol*. 2005; 57:721–9. [PubMed: 15852395]
35. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. *Alzheimers Dement*. 2010; 6:230–8. [PubMed: 20451871]
36. Farmer, JM.; McCarty-Wood, E.; Lee, VM-Y.; Trojanowski, JQ. An immortal legacy: how donation of human tissues impacts research and drives advances in diagnosis and therapy. In: Radin, L.; Radin, G., editors. *What if it's not Alzheimer's: a caregiver's guide to dementia*. New York: Prometheus Books; 2008. p. 129-44.
37. Ravid R, Van Zwieten EJ, Swaab DF. Brain banking and the human hypothalamus: factors to match for, pitfalls and potentials. *Prog Brain Res*. 1992; 93:83–95. [PubMed: 1480765]
38. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcu K, Hatanpaa KJ, et al. Human postmortem tissue: what quality markers matter? *Brain Res*. 2006; 1123:1–11. [PubMed: 17045977]
39. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. *J Histochem Cytochem*. 1989; 37:209–15. [PubMed: 2492045]
40. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of phosphate-independent MAP2 epitopes revealed with monoclonal antibodies in microwave-denatured human nervous system tissues. *J Neurosci Methods*. 1989; 29:171–80. [PubMed: 2475725]
41. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. *Brain*. 2012; 135:807–18. [PubMed: 22366796]
42. Vonsattel J, Amaya M, Keller C. Twenty-first century brain banking: processing brains for research: the Columbia University methods. *Acta Neuropathol*. 2008; 115:509–32. [PubMed: 17985145]
43. Lee EB, Skovronsky DM, Abtahian F, Doms RW, Lee VM. Secretion and intracellular generation of truncated Aβ in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. *J Biol Chem*. 2003; 278:4458–66. [PubMed: 12480937]
44. Thal DR, Rub U, Orantes M, Braak H. Phases of Aβ deposition in the human brain and its relevance for the development of AD. *Neurology*. 2002; 58:1791–800. [PubMed: 12084879]
45. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. *Ann Neurol*. 2002; 52:205–10. [PubMed: 12210791]

46. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 1991; 41:479–86. [PubMed: 2011243]
47. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. *Neurobiol Aging*. 1997; 18:S91–4. [PubMed: 9330994]
48. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. *Am J Pathol*. 2006; 169:1343–52. [PubMed: 17003490]
49. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. *Nat Commun*. 2011; 2:252. [PubMed: 21427723]

Further readings

- e1. Henchcliffe C, Dodel R, Beal MF. Biomarkers of Parkinson's disease and dementia with Lewy bodies. *Prog Neurobiol*. 2011; 95:601–13. [PubMed: 21983334]
- e2. Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degeneration: progress and challenges. *Prog Neurobiol*. 2011; 95:636–48. [PubMed: 21554923]
- e3. Ikonomic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain*. 2008; 131:1630–45. [PubMed: 18339640]
- e4. Davies DR, Gelinas AD, Zhang C, Rohloff JC, Carter JD, O'Connell D, et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. *Proc Natl Acad Sci U S A*. 2012; 109:19971–6. [PubMed: 23139410]
- e5. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. *N Engl J Med*. 2013; 368:117–27. [PubMed: 23150934]
- e6. Bell JE, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Budka H, et al. Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. *Acta Neuropathol*. 2008; 115:497–507. [PubMed: 18365220]
- e7. Dedova I, Harding A, Sheedy D, Garrick T, Sundqvist N, Hunt C, et al. The importance of brain banks for molecular neuropathological research: the New South Wales Tissue Resource Centre experience. *Int J Mol Sci*. 2009; 10:366–84. [PubMed: 19333451]
- e8. Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, Hu W, Greene R, Wood EM, et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. *Arch Neurol*. 2011; 68:488–97. [PubMed: 21482928]
- e9. Brettschneider J, Van Deerlin VM, Robinson JL, Kwong L, Lee EB, Ali YO, et al. Pattern of ubiquitin pathology in ALS and FTL indicates presence of C9ORF72 hexanucleotide expansion. *Acta Neuropathol*. 2012; 123:825–39. [PubMed: 22426854]
- e10. Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, Clark CM, et al. Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. *Arch Neurol*. 2007; 64:1148–53. [PubMed: 17698705]
- e11. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet*. 2011; 43:436–41. [PubMed: 21460841]
- e12. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet*. 2010; 42:234–9. [PubMed: 20154673]
- e13. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. *Arch Neurol*. 2009; 66:180–9. [PubMed: 19204154]

- e14. Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. *J Neurosci.* 2012; 32:11213–27. [PubMed: 22895706]
- e15. Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry.* 2013; 84:163–9. [PubMed: 23117491]
- e16. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol.* 2012; 72:587–98. [PubMed: 23037886]
- e17. Brettschneider J, Libon DJ, Toledo JB, Xie SX, McCluskey L, Elman L, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. *Acta Neuropathol.* 2012; 123:395–407. [PubMed: 22210083]
- e18. Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, Lee VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. *PLoS One.* 2012; 7:e39216. [PubMed: 22720079]
- e19. Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, et al. Comparison of cerebrospinal fluid levels of tau and Abeta 1–42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. *Arch Neurol.* 2012; 69:1018–25. [PubMed: 22490326]
- e20. Wang LS, Leung YY, Chang SK, Leight S, Knapik-Czajka M, Baek Y, et al. Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. *J Alzheimers Dis.* 2012; 31:439–45. [PubMed: 22571982]
- e21. McMillan CT, Avants B, Irwin DJ, Toledo JB, Wolk DA, Van Deerlin VM, et al. Can MRI screen for CSF biomarkers in neurodegenerative disease? *Neurology.* 2013; 80:132–8. [PubMed: 23269595]
- e22. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. *Lancet Neurol.* 2008; 7:409–16. [PubMed: 18396105]
- e23. [Accessed August 9, 2013] CNDR Biosample request forms and instructions. Available at: <http://www.med.upenn.edu/cndr/tissue.shtml>

Fig. 1.

Description of clinical, data, and sample integration in the Neuropathology, Biomarker, and Genetics Biobank. UPenn, University of Pennsylvania; PMC, Penn Memory Center; FTDC, Frontotemporal Dementia Center; PD&MDC, Parkinson's Disease and Movement Disorder Clinic; ALSC, Amyotrophic Lateral Sclerosis Center.